PARP Inhibition Delays Progression of Mitochondrial Encephalopathy in Mice

Neurotherapeutics

Volumn 11, Issue 3, 2014, Pages 651-664

  Felici, Roberta ^a   Cavone, Leonardo ^a   Lapucci, Andrea ^a   Guasti, Daniele ^b   Bani, Daniele ^b   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

complex I deficiency; mitochondrial biogenesis; Mitochondrial diseases; Ndufs4 knockout; PARP inhibitor; poly (ADP ribose) polymerase

Indexed keywords

N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; N-(OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)-N,N-DIMETHYLACETAMIDE HYDROCHLORIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, MOUSE; PHENANTHRENE DERIVATIVE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; BRAIN; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; EXPLORATORY BEHAVIOR; HOMEOSTASIS; LIVER; MITOCHONDRIAL ENCEPHALOPATHY; MOTOR CORTEX; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OLFACTORY BULB; PANCREAS; PRIORITY JOURNAL; SKELETAL MUSCLE; SPLEEN; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GLIA; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRIAL ENCEPHALOMYOPATHIES; MITOCHONDRION; MOTOR ACTIVITY; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; BRAIN; DISEASE PROGRESSION; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MITOCHONDRIAL ENCEPHALOMYOPATHIES; MOTOR ACTIVITY; NEUROGLIA; NEURONS; OXIDATIVE STRESS; PHENANTHRENES; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84905569779     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0285-y     Document Type: Article

References (47)

1. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999;283: 1482-1488.
2. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010;5: 297-348.
3. Sofou K. Mitochondrial disease: a challenge for the caregiver, the family, and society. J Child Neurol 2013;28: 663-667.
4. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012;4: CD004426.
5. Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov 2013;12: 465-483.
6. Koene S, Willems PH, Roestenberg P, Koopman WJ, Smeitink JA. Mouse models for nuclear DNA-encoded mitochondrial complex I deficiency. J Inherit Metab Dis 2011;34: 293-307.
7. Valsecchi F, Koopman WJ, Manjeri GR, et al. Complex I disorders: causes, mechanisms, and development of treatment strategies at the cellular level. Dev Disabil Res Rev 2010;16: 175-182.
8. Kruse SE, Watt WC, Marcinek DJ, et al. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab 2008;7: 312-320.
9. Quintana A, Kruse SE, Kapur RP, Sanz E, Palmiter RD. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc Natl Acad Sci U S A 2010;107: 10996-11001.
10. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer 2012;12: 741-752.
11. Canto C, Auwerx J. NAD+ as a signaling molecule modulating metabolism. Cold Spring Harb Symp Quant Biol 2011;76: 291-298.
12. Houtkooper RH, Auwerx J. Exploring the therapeutic space around NAD+. J Cell Biol 2012;199: 205-209.
13. D'Amours D, Desnoyers S, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342: 249-268.
14. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012;13: 411-424.
15. Kraus WL. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008;20: 294-302.
16. Kraus WL, Lis JT. PARP goes transcription. Cell 2003;113: 677-683.
17. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 2010;31: 212-220.
18. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009;20: 98-105.
19. Zhang T, Berrocal JG, Frizzell KM, et al. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem 2009;284: 20408-20417.
20. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005;280: 43121-43130.
21. Bai P, Canto C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011;13: 461-468.
22. Pittelli M, Felici R, Pitozzi V, et al. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol Pharmacol 2011;80: 1136-1146.
23. Canto C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15: 838-847.
24. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4: 421-440.
25. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10: 293-301.
26. Papeo G, Forte B, Orsini P, et al. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 2009;19: 1377-1400.
27. Kuribara H, Higuchi Y, Tadokoro S. Effects of central depressants on rota-rod and traction performances in mice. Jpn J Pharmacol 1977;27: 117-126.
28. Pittelli M, Cavone L, Lapucci A, et al. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes. Immunol Cell Biol 2014;92: 191-199.
29. Felici R, Lapucci A, Ramazzotti M, Chiarugi A. Insight into molecular and functional properties of NMNAT3 reveals new hints of NAD homeostasis within human mitochondria. PLoS One 2013;8: e76938.
30. Faraco G, Pittelli M, Cavone L, et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009;36: 269-279.
31. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic Acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006;70: 1876-1884.
32. Dimauro S, Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 2009;1792: 1159-1167.
33. Chiarugi A. PARP-1: killer or conspirator? The suicide hypothesis revisited. Trends Pharmacol Sci 2002;23: 122-129.
34. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30: 283-288.
35. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008;88: 611-638.
36. Pellicciari R, Camaioni E, Costantino G, et al. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. Chem Med Chem 2008;3: 914-923.
37. Bai P, Canto C, Brunyanszki A, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 2011;13: 450-460.
38. Iuso A, Scacco S, Piccoli C, et al. Dysfunctions of cellular oxidative metabolism in patients with mutations in the NDUFS1 and NDUFS4 genes of complex I. J Biol Chem 2006;281: 10374-10380.
39. Quintana A, Zanella S, Koch H, et al. Fatal breathing dysfunction in a mouse model of Leigh syndrome. J Clin Invest 2012;122: 2359-2368.
40. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009;218: 193-202.
41. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 2003;85: 306-317.
42. Oei SL, Shi Y. Poly(ADP-ribosyl)ation of transcription factor Yin Yang 1 under conditions of DNA damage. Biochem Biophys Res Commun 2001;285: 27-31.
43. Hossain MB, Ji P, Anish R, Jacobson RH, Takada S. Poly(ADP-ribose) polymerase 1 interacts with nuclear respiratory factor 1 (NRF-1) and plays a role in NRF-1 transcriptional regulation. J Biol Chem 2009;284: 8621-8632.
44. Lapucci A, Pittelli M, Rapizzi E, et al. Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol 2011;79: 932-940.
45. Johnson SC, Yanos ME, Kayser EB, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 2013;342: 1524-1528.
46. Cerutti R, Pirinen E, Lamperti C, et al. NAD-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014;19: 1042-1049.
47. Pirinen E, Canto C, Jo YS, et al. Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;9: 1034-1041.